Ra Pharmaceuticals (NASDAQ:RARX) had its price objective lowered by equities research analysts at Credit Suisse Group from $16.00 to $14.00 in a report released on Tuesday. The firm presently has an “outperform” rating on the stock. Credit Suisse Group’s target price would indicate a potential upside of 118.75% from the stock’s previous close.
RARX has been the topic of several other reports. ValuEngine cut shares of Ra Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. BMO Capital Markets restated an “outperform” rating and set a $34.00 target price (up from $31.00) on shares of Ra Pharmaceuticals in a research report on Monday, December 4th. Zacks Investment Research cut shares of Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 11th. Finally, Royal Bank of Canada restated a “buy” rating and set a $18.00 target price on shares of Ra Pharmaceuticals in a research report on Tuesday, December 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $20.10.
Shares of Ra Pharmaceuticals (NASDAQ:RARX) opened at $6.40 on Tuesday. The company has a market cap of $142.55, a price-to-earnings ratio of -2.59 and a beta of 2.15. Ra Pharmaceuticals has a one year low of $5.90 and a one year high of $27.84.
COPYRIGHT VIOLATION NOTICE: “Ra Pharmaceuticals (RARX) Price Target Cut to $14.00” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/13/ra-pharmaceuticals-rarx-price-target-cut-to-14-00.html.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.